Why Novel Nanoparticle-based Delivery Platforms Hold Key for HIV/AIDS Treatment and Prevention?

Authors

  • Michael Ochieng Otieno Department of Biochemistry and Molecular Biology, Georgetown University, Washington DC, USA

DOI:

https://doi.org/10.17140/HARTOJ-2-113

Keywords:

Nanoparticle, Regimens, Nanotechnology, nanoART

Abstract

The administration of highly active antiretroviral therapy (HAART) to HIV/AIDS patients has greatly reduced their morbidity and mortality. However, HAART regimens have myriad of limitations, which make it difficult to completely eradicate HIV/AIDS from the body. Cells harboring latent HIV reside in restricted areas in the body: cellular and anatomical reservoirs. The residing of HIV in these restricted sanctuaries makes HAART regimens incapable of completely eliminating HIV from the body.

References

Lamers SL, Salemi M, Galligan DC, et al. Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology. PLoS One. 2009; 4(3): E5065. doi: 10.1371/ journal.pone.0005065

Marsden MD, Zack JA. Eradication of HIV: Current challeng-es and new directions. J Antimicrob Chemother. 2009; 63(1): 7-10. doi: 10.1093/jac/dkn455

Richman DD, Margolis DM, Delaney M, Greene WC, Ha-zuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009; 323(5919): 1304-1307. doi: 10.1126/ science.1165706

Mamo T, Moseman EA, N Kolishetti N, et al. Emerging nan-otechnology approaches for HIV/AIDS treatment and preven-tion. Nanomedicine (Lond). 2010; 5(2): 269-285. doi: 10.2217/ nnm.10.1

Nowacek A, Gendelman HE. Nanoart, neuroAIDS and CNS drug delivery. Nanomed. 2009; 4(5): 557-574. doi: 10.2217/ nnm.09.38

Leonard B. Class presentation on Core methods of Biotech-nology. 21.

Farokhzad OC. Nanotechnology for drug delivery: The per-fect partnership. Expert Opin Drug Deliv. 2008; 5(9): 927-929. doi: 10.1517/17425247.5.9.927

Edagwa BJ, Zhou T, McMillan JM, Liu XM, Gendelman HE. Development of HIV Reservoir Targeted Long Acting Nano-formulated Antiretroviral Therapies. Curr Med Chem. 2014; 21(36): 4186-4198.

Destache CJ. Chapter 12-Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option. Progress in brain research. 2009; 180: 225-233. doi: 10.1016/S0079- 6123(08)80012-X

Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nano-technology applications for improved delivery of antiretroviral drugs to the brain. Advanced Drug Delivery Reviews. 2010; 62(4-5): 503-517. doi: 10.1016/j.addr.2009.11.020

Guo D. Endosomal Trafficking of Nanoformulated Antiretro-viral Therapy Facilitates Drug Particle Carriage and HIV Clear-ance. Journal of Virology. 2014; 88: 9504-9513. doi: 10.1128/ JVI.01557-14

Puligujja P, Balkundi SS, Kendrick LM, et al. Pharmaco-dynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations, Biomaterials. 2015; 41: 141-150. doi: 10.1016/j.biomaterials.2014.11.012

Guo D, Zhang G, Wysocki TA, et al. Endo-somal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. J Virol. 2014; 88: 9504-9513. doi: 10.1128/JVI.01557-14

Puligujja P, McMillan J, Kendrick L, et al. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human im- munodeficiency virus infections. Nano-med Nanotechnol Biol Med. 2013; 9: 1263-1273. doi: 10.1016/j. nano.2013.05.003

Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol. 2007; 25(12): 1444-1454. doi: 10.1038/nbt1367

Dizaj SM, Jafari S, Khosroushahi AY. A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Research Letters. 2014; 9: 252. doi: 10.1186/1556-276X-9-252

Lundin KE, Simonson OE, Moreno PM, et al. Nanotechnol-ogy approaches for gene transfer. Genetica. 2009; 137(1): 47- 56. doi: 10.1007/s10709-009-9372-0

Mintzer MA, Simanek EE. Nonviral vectors for gene deliv-ery. Chem Rev. 2009; 109(2): 259-302. doi: 10.1021/cr800409e

Haasnoot J, Westerhout EM, Berkhout B. Rna interference against viruses: strike and counterstrike. Nat Biotechnol. 2007; 25(12): 1435-1443. doi: 10.1038/nbt1369

Lee JM, Yoon TJ, Cho YS. Recent developments in nanopar-ticle-based siRNA delivery for cancer therapy. Biomed Res Int. 2013; 782041(10): 17. doi: 10.1155/2013/782041

Lian J, Xin Z, Ming L, Yan D, Nongyue H. Current prog-ress in gene delivery technology based on chemical methods and nano-carriers. Theranostics. 2014; 4(3): 240-255. doi: 10.7150/ thno.6914

Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiological-ly based pharmacokinetic modeling of nanoparticles. ACS Nano. 2010; 4: 6303-6317. doi: 10.1021/nn1018818

Solmaz Mamo T, Moseman EA, Kolishetti N, et al. Emerg-ing nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine. 2010; 5(2): 269-285. doi: 10.2217/ nnm.10.1

Ramos-Perez V, Cifuentes A, Coronas N, Pablo A, Borrós S. Modification of carbon nanotubes for gene delivery vectors: nanomaterial interfaces in biology. Methods Mol Biol. 2013; 1025: 261-268. doi: 10.1007/978-1-62703-462-3_20

Rinaldo CR. Dendritic cell-based human immunodeficien-cy virus vaccine. J Intern Med. 2009; 265(1): 138-158. doi: 10.1111/j.1365-2796.2008.02047.x

Jihed C, Campbell Donald E, Livio A, et al. Persistent de-creases in blood plasmacytoid dendritic cell number and func-tion despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in hiv-infected indi-viduals. J Immunol. 2002; 168: 4796-4801. doi: 10.4049/ jim-munol.168.9.4796

Lori F, Calarota SA, Lisziewicz J. Nanochemistry-based im-munotherapy for HIV-1. Curr Med Chem. 2007; 14(18): 1911- 1919.

Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455(7213): 613-619. doi: 10.1038/na-ture07352

Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigore-na S. Antigen presentation and t cell stimulation by dendritic cells. Ann Rev Immunol. 2002; 20: 621-667. doi: 10.1146/an-nurev.immunol.20.100301.064828

Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev. 2009; 61(2): 140-157. doi: 10.1016/j.addr.2008.09.005

Date AA, Destache CJ. A review of nanotechnological ap-proaches for the prophylaxis of HIV/AIDS. Biomaterials. 2013; 34(26): 6202-6228. doi: 10.1016/j.biomaterials.2013.05.012

Aline F, Brand D, Pierre J, et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine. 2009; 27: 5284-5289. doi: 10.1016/j.vaccine.2009.05.028

Raveen P, Maguire GEM, Govender P, Kruger HG. Nano-technology and the Treatment of HIV Infection. Viruses. 2012; 4: 488-520. doi: 10.3390/v4040488

Müller RH, Gohla S, Keck CM. State of the art of nanocrys-tals-Special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm. 2011, 78: 1-9. doi: 10.1016/j.ejpb.2011.01.007

Ochekpe NA, Olorunfemi PO, Ngwuluka NC. Nanotechnol-ogy and drug delivery part 2: Nanostructures for drug delivery. Trop. J. Pharm. Res. 2009; 8: 275-287.

Rama M, Lisa RC. Progress in antiretroviral drug delivery using nanotechnology. International Journal of Nanomedicine. 2010; 5: 533-547.

Downloads

Published

2015-08-27

How to Cite

Michael Ochieng Otieno. (2015). Why Novel Nanoparticle-based Delivery Platforms Hold Key for HIV/AIDS Treatment and Prevention?. HIV/AIDS/Research/and/Treatment, 2(3), 81–85. https://doi.org/10.17140/HARTOJ-2-113

Issue

Vol. 2 No. 3 (2015): Volume 2 Issue 3 2015

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in HIV/AIDS Research and Treatment (HRT) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.